ArticleAntibiotics (Basel, Switzerland)2021
Synergistic Meropenem/Vaborbactam Plus Fosfomycin Treatment of KPC Producing
Article in Antibiotics (Basel, Switzerland), 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 25 citations in OpenAlex.
- Article
- TDM-guided meropenem/vaborbactam-based therapy for successful treatment of intra-abdominal and bloodstream infection caused by KPC-producing ceftazidime/avibactam-resistant Klebsiella pneumoniae in a paediatric liver transplant recipient.The Journal of antimicrobial chemotherapy · 2025Article
- Meropenem-Vaborbactam for Treatment of Carbapenem-Resistant Enterobacterales: A Narrative Review of Clinical Practice Evidence.Infectious diseases and therapy · 2025Review
- Overcoming the drug resistance barrier: progress in fosfomycin combination therapy against multidrug-resistant pathogens.Frontiers in microbiology · 2025Review
- Short Course Antibiotic Therapy for Catheter-Related Septic Thrombosis: "Caveat Emptor!": Duration of Therapy Should Not Be SetPathogens (Basel, Switzerland) · 2024Review
- Synergistic Activity of Temocillin and Fosfomycin Combination against KPC-ProducingAntibiotics (Basel, Switzerland) · 2024Article
- Antimicrobial and Diagnostic Stewardship of the Novel β-Lactam/β-Lactamase Inhibitors for Infections Due to Carbapenem-Resistant Enterobacterales Species andAntibiotics (Basel, Switzerland) · 2024Review
- Efficacy of new generation biosorbents for the sustainable treatment of antibiotic residues and antibiotic resistance genes from polluted waste effluent.Infectious medicine · 2024Review
- Mutations inJAC-antimicrobial resistance · 2023Article
- Resistance to Ceftazidime/Avibactam inAntibiotics (Basel, Switzerland) · 2023Article
- What to Do with the New Antibiotics?Antibiotics (Basel, Switzerland) · 2023Review
- Intravenous Fosfomycin: A Potential Good Partner for Cefiderocol. Clinical Experience and Considerations.Antibiotics (Basel, Switzerland) · 2022Article
- Effect of ceftazidime/avibactam plus fosfomycin combination on 30 day mortality in patients with bloodstream infections caused by KPC-producingJAC-antimicrobial resistance · 2022Article
- Oral Fosfomycin Formulation in Bacterial Prostatitis: New Role for an Old Molecule-Brief Literature Review and Clinical Considerations.Infectious disease reports · 2022Review
- New Antimicrobial Options in the Clinical Practice of Infections Caused by Difficult-to-Treat Pathogens: A Global Opportunity for Public Health.Antibiotics (Basel, Switzerland) · 2022Article
- Place in Therapy of the Newly Available Armamentarium for Multi-Drug-Resistant Gram-Negative Pathogens: Proposal of a Prescription Algorithm.Antibiotics (Basel, Switzerland) · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Gram-negative bacilli septic thrombosis (GNB-ST) represents a subtle and often misleading condition, potentially fatal if not recognized early and requiring prolonged antimicrobial therapy and anticoagulation. Herein, reported for the first time, is a very challenging case of
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.